Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Quantification of BIM mRNA in circulating tumor cells of osimertinib-treated patients with EGFR mutation-positive lung cancer.

Respiratory investigation - 1 Jul 2021

Isobe Kazutoshi, Yoshizawa Takahiro, Sekiya Muneyuki, Miyoshi Shion, Nakamura Yasuhiko, Urabe Naohisa, Isshiki Takuma, Sakamoto Susumu, Takai Yujiro, Tomida Taichiro, Adachi-Akahane Satomi, Iyoda Akira, Homma Sakae, Kishi Kazuma

Abstract excerpt

BACKGROUND: The response rate for osimertinib is high among patients with untreated epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). However, there exist no biomarkers to predict the efficacy of the same. This study investigated whether BIM-γ mRNA expression in circulating tumor cells (CTCs) predicts poor outcomes for osimertinib treatment in patients with EGFR...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Neoplasm Recurrence, Local

Share to Neoplastic Cells, Circulating

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 33934994
DOI: 10.1016/j.resinv.2021.03.010

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Quantification of BIM mRNA in circulating tumor cells of osimertinib-treated patients with EGFR mutation-positive lung cancer.PMID 33934994Read ↗

A Phase II Trial of Osimertinib as the First-Line Treatment of Non-Small Cell Lung Cancer Harboring Activating EGFR Mutations in Circulating Tumor DNA: LiquidLung-O-Cohort 1.Semantic proximity Read ↗

The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial.Semantic proximity Read ↗

Upfront treatment with osimertinib in lung cancer patients with and without active brain metastases, and the role of ctDNA as a biomarker; a phase II clinical trial (the FIOL study).Semantic proximity Read ↗

Assessment of Anti-tumor Efficacy of Osimertinib in Non-Small Cell Lung Cancer Patients by Liquid Biopsy Using Bronchoalveolar Lavage Fluid, Plasma, or Pleural Effusion.Semantic proximity Read ↗

Association of BIM Deletion Polymorphism and BIM-γ RNA Expression in NSCLC with EGFR Mutation.Semantic proximity Read ↗

EGFR Inhibitors Plus Bevacizumab are Superior Than EGFR Inhibitors Alone as First-Line Setting in Advanced NSCLC With EGFR Mutations and BIM Deletion Polymorphisms (BIM-CLICaP).Semantic proximity Read ↗

Clearing of circulating tumour DNA predicts clinical response to osimertinib in EGFR mutated lung cancer patients.Semantic proximity Read ↗

Efficacy of EGFR tyrosine kinase inhibitors in patients having EGFR-activating mutations with or without BIM polymorphisms.Semantic proximity Read ↗

Tumour Content Ratio Matters for Detecting Epidermal Growth Factor Receptor Mutation by Cobas Test in Small Biopsies; a Retrospective StudySemantic proximity Read ↗

BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer.Semantic proximity Read ↗

Role of BIM Deletion Polymorphism and BIM Expression as Predictive Biomarkers to Maximize the Benefit of EGFR-TKI Treatment in EGFR-Positive NSCLC.Semantic proximity Read ↗

Tumour content ratio matters for detecting epidermal growth factor receptor mutation by cobas test in small biopsies; a retrospective study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.